MTHFR C677T Polymorphism and Its Relation to Ischemic Stroke in the Black Sea Turkish Population

American Journal of Hematology

Volumn 76, Issue 1, 2004, Pages 40-43

  Uçar, Fahri ^a   Sönmez, Mehmet ^a   Ovali, Ercüment ^a   Özmenoǧlu, Mehmet ^a   Karti, S Sami ^a   Yilmaz, Mustafa ^a   Pakdemir, Alper ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Black Sea Turkish population; Ischemic stroke; MTHFR polymorphism; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; AGED; ALLELISM; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TURKEY (REPUBLIC); VEIN THROMBOSIS;

ADULT; AGED; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; OCEANS AND SEAS; POLYMORPHISM, GENETIC; PREVALENCE; TURKEY;

EID: 17144452539     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20050     Document Type: Article

References (43)

1. Hart RG, Miller VT. Cerebral infarction in young adults: a practical approach. Stroke 1983;14:110-114.
2. Madonna P, de Stafano V, Coppola A, et al. Hyperhomocysteinemia and other inherited prothrombic conditions in young adults with a history of ischemic stroke. Stroke 2002;33:51-56.
3. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
4. Dahlbäck B. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997;78:483-488.
5. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
6. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988;43:414-421.
7. De Stefano V, Rossi E, Pacioroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002;87:1095-1108.
8. Akar N, Akar E, Misirlioglu M, Avcu F, Yalcin A, Cin S. Search for genetic factors favoring thrombosis in Turkish population. Thromb Res 1998;92:79-82.
9. Akar N, Akar E, Akcay R, Avcu F, Yalcin A, Cin S. Effect of methylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients. Thromb Res 2000;97:163-167.
10. Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001;27:362-367.
11. Rozen R, Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase. Thromb Haemost 1997;78:523-526.
12. Linfert DR, Tsongalis GJ. Co-existence of the methylenetetrahydrofolate reductase single-nucleotide polymorphism (C677T) in patients with the factor V Leiden or prothrombin G20210A polymorphisms. Diagn Mol Pathol 2001;10:111-115.
13. Kang SS, Wong PWK, Bock HG, Horwitz A, Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 1991;38:546-551.
14. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 1999;93:1-8.
15. Voetsch B, Damasceno BP, Camargo EC, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000;83:229-233.
16. Akar N, Akar E, Deda G, Sipahi T, Orsal A. Factor V1691 G-A, prothrombin 20210 G-A, and methylenetetrahydrofolate reductase 677 C-T variants in Turkish children with cerebral infarct. J Child Neurol 1999;14:749-751.
17. Lopaciuk S, Bykowska K, Kwiecinski H, et al. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost 2001;7:346-350.
18. Akar N, Akar E, Ozel D, Deda G, Sipahi T. Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res 2001;102:115-120.
19. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 1999;81:733-738.
20. Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 1999;61:265-267.
21. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002;59:529-536.
22. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure of extracting DNA from human nucleated cells. Nucleic Acids Res 1998;16:1215.
23. Wilde JT, O'Sullivan JJ, Roper JL, Aerts P, Horowitz M, Navot N. A novel ELISA-based primer extension assay for the detection of the factor V Leiden mutation. Br J Haematol 1999;106:427-430.
24. Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J Med Sci 2001;47:255-262.
25. Zheng Y-Z, Tong J, Do X-P, Pu X-Q, Zhou B-T. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol 2000;109:870-874.
26. Gürgey A, Rustemov R, Parlak H, Balta G. Prevalence of FV Leiden and methylenetetrahyrofolate reductase C677T mutations in Azerbaijan population. Thromb Haemost 1998; 80:520-521.
27. Gaustadnes M, Rudiger N, Moller J, Rasmussen K, Bjerregaard Larsen T, Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis 1999;10:251-259.
28. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917.
29. Laouschek W, Aull S, Serles W, et al. C677T MTHFR mutation and factor V Leiden mutation patients with TIA/minor stroke: a case control study. Thromb Res 1999;93:61-69.
30. Press RD, Liu XY, Beamer N, Coul BM. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996;27:44-48.
31. Markus HS, Zhang Y, Jeffery S. Screening for the factor-V Arg 506 Gln mutation in patients with TIA and stroke. Cerebrovasc Dis 1996;6:360-362.
32. Vanderborm JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265.
33. Catto A, Carter A, Grant PJ. Factor V Leiden mutation and completed stroke. Stroke 1996;27:573.
34. Harmon DL, Doyle RM, Meleady R, et al. Genetic analysis of the thermolabile variant of 5,10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol 1999;99:208-211.
35. Reuner KH, Ruf A, Kaps M, Druschky KF, Patscheke H. The mutation C677T in the methylenetetrahydrofolate reductase gene and stroke. Thromb Haemost 1998;79:450-451.
36. Morita H, Kurihara H, Tsubaki S, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998;18:1465-1469.
37. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-1916.
38. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
39. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930-2936.
40. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-1782.
41. Mandel H, Brenner B, Berant M, et al. Co-existence of hereditary homocystinuria and factor V Leiden: effect on thrombosis. N Engl J Med 1996;334:763-768.
42. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398.
43. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, deGarmo P. Elevated plasma homocysteine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-576.